Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek's disease vaccine with an insertion of the long terminal repeat of reticuloendotheliosis virus in the CVI988 strain genome (CVI-LTR)

Nik M Faiz; Aneg L Cortes; Yuen-Fun Phang; Isabel M Gimeno

doi:10.1080/03079457.2024.2324930

Optimizing protocols for monitoring in vivo replication of a novel chimeric Marek's disease vaccine with an insertion of the long terminal repeat of reticuloendotheliosis virus in the CVI988 strain genome (CVI-LTR)

Avian Pathol. 2024 Mar 20:1-9. doi: 10.1080/03079457.2024.2324930. Online ahead of print.

Authors

Nik M Faiz¹, Aneg L Cortes^{2

3}, Yuen-Fun Phang⁴, Isabel M Gimeno²

Affiliations

¹ Department of Veterinary Clinical Studies, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang, Malaysia.
² Department of Population Health and Pathobiology, Veterinary School, North Carolina State University, Raleigh, NC, USA.
³ Duke University Center for Human Systems Immunology, Duke University School of Medicine, Durham, NC, USA.
⁴ Boehringer Ingelheim Animal Health Singapore, Guoco Midtown, Singapore.

PMID: 38411905
DOI: 10.1080/03079457.2024.2324930

Abstract

CVI-LTR replicates in the thymus and spleen earlier than CVI988.CVI-LTR replicates in lymphoid organs but it cannot be detected in feather pulp.CVI-LTR reduced the load of oncogenic MDV DNA more efficiently than CVI988.

Keywords: LTR; Marek’s disease; feather pulp; lymphoid organs; monitoring; vaccines.